Connect with us

Technology

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Published

on

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.

HENDERSON, Nev., Aug. 5, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition today announces the publication of the first peer-reviewed paper describing the technology in detail – entitled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1“.

Most current liquid biopsy methods involve deep sequencing of plasma DNA and bioinformatic analysis of the data produced to identify the presence of cancer in a patient. The biggest problem facing all liquid biopsy methods worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. Volition’s new technology employs an entirely novel approach to liquid biopsy that has overcome this hurdle and produced >99% pure cancer associated plasma DNA sequence sets for liquid biopsy.

Mr. Gael Forterre, Chief Licensing Officer, Volition added:

“We are delighted that the paper detailing this breakthrough technology has been peer reviewed and published.

“We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of this technology, “Capture-Seq™”,  and indeed are in the process of undertaking technical evaluations with potential licensors.  

“We believe the potential use cases for Capture-Seq™ represent a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $23 billion2 for the human Multi-Cancer Early Detection (MCED) use, and over $13 Billion2 for Minimum Residual Disease (MRD).”

Dr Jake Micallef, Chief Scientific Officer, Volition commented:

“Distinguishing cancer derived plasma DNA from healthy DNA when the two are mixed is problematic as they are chemically similar. As the cancer DNA may make up 1% or less of the total DNA, it is extremely problematic. 

“Our manuscript describes a new liquid biopsy chemistry for isolating CTCF-DNA from plasma. Our work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA.

“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years.

“In this published paper we report a new, two-step method for preparing pure circulating tumor DNA data sets for cancer patients:

physical enrichment of the sample; andbioinformatic removal of virtually all remaining non-tumor cfDNA sequences from the DNA sequence data set.

“This new method produced >99% pure ctDNA sequencing data sets for blood samples from cancer patients and, whilst we capture a subset of the ctDNA (i.e. not all the ctDNA in a sample), it is virtually pure cancer DNA.

“These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers. Capture-Seq™ shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease (MRD).

“We are fast-tracking the development of Capture-Seq™ conducting further studies, including competing conditions and larger sample sets and working with oncology Key Opinion Leaders.

“Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology.”

Dr Andrew Retter, Medical Consultant, Volition commented:

“From a clinical perspective, the proof of concept and early blinded validation results reported in this paper are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional controls.  

“We have also subsequently reported data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and are extremely encouraged by the results; the early-stage cancer detection of 95% of stage I and II cancers is particularly noteworthy.

“For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.

“We also believe that Capture-Seq™ has the potential to play a role in cancer management, including but not limited to, Minimal Residual Disease detection and treatment monitoring, either alone or potentially in combination with other technologies too.”

Pamart, D., et al. Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy. Clin Epigenet (2026). https://doi.org/10.1186/s13148-026-02205-xData on File : Volition TAM Model

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com,+44 (0)7557 774620

Safe Harbor Statement

Statements contained or referenced herein, including in any associated video or link, may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify such statements.

These forward-looking statements relate to, among other topics, Volition’s expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases; its expectations regarding future publications; and its success in securing, and the terms of, licensing and/or distribution agreements with third parties.

Forward-looking statements are based on current expectations, estimates and projections about Volition’s business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: the results of studies testing the efficacy of Volition’s tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.

Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.

Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volition-reports-publication-of-first-peer-reviewed-paper-on-new-capture-seq-liquid-biopsy-technology-302843578.html

SOURCE VolitionRx Limited

Continue Reading

Technology

Built for Extreme Resilience: ATEN Unveils Its First Industrial-Grade KVM over IP Extender and Wins Good Design Award 2026

Published

on

By

Engineered for Harsh Maritime Environments with International Maritime Certifications, Conformal-Coated Protection, and Salt-Fog Resistance

TAIPEI, Nov. 20, 2026 /PRNewswire/ — ATEN International, the global leader in intelligent control solutions, announced the launch of the ATEN KE6948A Rugged DVI-I Dual-Display KVM over IP Extender, its first industrial-grade KVM over IP extender designed for mission-critical operations in extreme environments. As part of the ATEN KVM over IP Matrix System, which has been honored with the Good Design Award 2026, the KE6948A combines rugged durability, Maritime-certified reliability, and advanced KVM over IP technology to deliver secure and dependable remote control across demanding applications.

Engineered to withstand demanding maritime conditions, the KE6948A meets DNV certification requirements, and complies with IACS E10 and IEC 60945 standards, delivering reliable performance in challenging operating environments. Designed for applications across land, air, and sea, it provides a rugged foundation for KVM over IP deployments in control rooms, energy facilities, aviation operations, maritime infrastructure, and other mission-critical environments where continuous operation and system security are essential. In mission-critical environments, resilience goes beyond rugged hardware. It also means maintaining secure, uninterrupted access and control when physical access is limited, operating conditions are harsh, or unexpected disruptions occur.

To ensure long-term reliability, the KE6948A features a fanless passive heat dissipation design with an extruded chassis that facilitates natural airflow for efficient heat dissipation. Its conformal-coated PCB provides enhanced protection against humidity, dust, and corrosion, while salt-fog resistance and wide-temperature operation further reinforce its durability. Together, these industrial-grade features help ensure stable, uninterrupted performance and strengthen operational resilience in demanding environments where equipment failure is not an option.

Beyond its rugged construction, the KE6948A enables operators to remotely access and control critical systems from command stations, keeping personnel safely separated from equipment operating in hazardous or restricted areas. The system ensures robust air-gapped security through hardware-level network isolation, separating the dedicated KVM over IP network from external networks to help safeguard critical infrastructure and sensitive data transmission. When integrated with ATEN’s CCKM (KVM over IP Matrix Manager), the KE6948A becomes part of a scalable, many-to-many KVM over IP matrix architecture, enabling centralized monitoring, configuration, and troubleshooting from a single management platform.

For more information about the ATEN KE6948A Rugged DVI-I Dual-Display KVM over IP Extender, please visit: https://www.aten.com/eu/en/products/kvm/kvm-extenders/ke6948a/

Media Contact:
Sunny Peng
sunnypeng@aten.com.tw 
0286926789 #1835

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/built-for-extreme-resilience-aten-unveils-its-first-industrial-grade-kvm-over-ip-extender-and-wins-good-design-award-2026-302946665.html

Continue Reading

Technology

Sailun Group Attends COP31, Showcasing Green Practices Driven by Technological Innovation

Published

on

By

ANTALYA, Türkiye, Nov. 20, 2026 /PRNewswire/ — The 31st Conference of the Parties to the United Nations Framework Convention on Climate Change (COP31) was held in Antalya, Türkiye, from November 9 to 20. As a representative of the green transformation of the rubber and tire industry, Sailun Group was invited to attend the conference, where Chairwoman Yanhua Liu shared the company’s innovative practices and achievements in climate action and sustainable development.

Guided by its ESG principles, Sailun Group continues to leverage technological innovation to explore low-carbon development pathways across the entire life cycle of rubber tires, delivering practical and scalable solutions. Liu noted that Sailun originated from Qingdao University of Science and Technology, and that technological innovation and sustainability have been embedded in its corporate DNA since its founding.

After more than a decade of R&D, Sailun pioneered Eco Point3 Tires, achieving green, low-carbon, and sustainable development throughout the product life cycle, from raw material selection and manufacturing to product use. The technology also enhances three key performance attributes—wet handling, low rolling resistance, and wear resistance—overcoming the century-old “Magic Triangle” challenge in the tire industry while significantly reducing energy consumption and carbon emissions.

Liu emphasized that sustainability gives a new meaning to a “good tire”: safer for drivers, more resource-efficient, and more environmentally friendly. Through technological innovation, Sailun is contributing practical solutions from the rubber industry to global climate action.

As a member of the United Nations Global Compact (UNGC) and the World Business Council for Sustainable Development (WBCSD), Sailun actively participates in global climate initiatives. Sailun currently holds an AA rating in the MSCI ESG Ratings, placing it among the leading companies in the global tire industry. It is also the first tire company in China to have its science-based emissions reduction targets validated by the Science Based Targets initiative (SBTi), leveraging technological innovation to accelerate the green and low-carbon transformation of the global tire industry.

With its global footprint, Sailun is evolving from a participant to an explorer and driver of global climate action. Liu stated that Sailun will continue to focus on customer needs and leverage advanced technologies and quality services to provide safe, comfortable, and energy-efficient products and services to customers worldwide.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sailun-group-attends-cop31-showcasing-green-practices-driven-by-technological-innovation-302946683.html

SOURCE Sailun Group

Continue Reading

Technology

PhotonPay Strengthens Its Global Presence at Singapore FinTech Festival 2026

Published

on

By

The company showcased its integrated financial capabilities, engaged with industry leaders and hosted an exclusive networking event during the three-day festival.

HONG KONG, Nov. 20, 2026 /PRNewswire/ — PhotonPay, the next-generation financial operating system, exhibited at the Singapore FinTech Festival (SFF) 2026 from November 18–20 at Singapore EXPO. At Booth 3F13, the company welcomed visitors from across the global financial and technology ecosystem, presenting its capabilities and discussing the evolving needs of businesses operating internationally.

Under the theme “The Coming Rewiring of the Financial System: New Risks. New Rules. New Growth,” SFF 2026 brought together policymakers, financial institutions, technology providers and business leaders to examine the forces reshaping global finance. This year’s discussions spanned AI-driven financial services, cross-border payments, evolving regulatory frameworks and the future of financial infrastructure, highlighting how the industry is adapting to an increasingly interconnected global economy.

For PhotonPay, the festival offered an opportunity to showcase its approach to simplifying global financial operations while gaining first-hand insights into the challenges and opportunities shaping international business.

Showcasing Capabilities on the Exhibition Floor

Throughout the three-day exhibition, PhotonPay’s team engaged with industry peers, existing partners and prospective clients at its booth. Many discussions focused on a shared challenge facing internationally active businesses: managing payments and financial operations across multiple markets without adding unnecessary complexity.

International expansion requires more than access to individual payment channels. Businesses also need reliable local collection, cross-border payouts, foreign exchange and commercial card services to keep funds moving and operations running smoothly.

PhotonPay showcased its integrated financial services, including multi-currency wallet capabilities, global payment and payout solutions, foreign exchange and card issuing. By bringing these capabilities together within a unified infrastructure, PhotonPay aims to help businesses navigate different markets and manage their financial operations with greater flexibility.

A broader theme also emerged across the festival: as global commerce becomes more distributed and financial services continue to evolve, connectivity, local market access and operational efficiency are becoming increasingly important to businesses pursuing international growth.

Industry Engagement and Market Expansion

Alongside its exhibition activities, PhotonPay’s leadership team met with senior representatives from Mastercard and Visa to discuss developments in the global payments industry and the evolving requirements of businesses operating across borders.

The team also held discussions with representatives of the Dutch Ministry of Finance and the Netherlands Foreign Investment Agency (NFIA), exploring the Dutch financial market, its regulatory environment and opportunities for PhotonPay’s future expansion in Europe. These exchanges provided valuable insights into the local business landscape as the company continues to assess opportunities in the region.

Taking the Conversation Beyond the Exhibition Floor

On November 18, PhotonPay hosted After Dark with PhotonPay, an invitation-only side event at SKAI Bar, bringing together guests from across the fintech and financial services community.

With panoramic views of Singapore’s skyline, the evening provided a relaxed setting for partners, industry peers and friends to meet and exchange ideas, accompanied by live acoustic music and drinks.

PhotonPay’s participation in SFF 2026 reflects its continued commitment to supporting businesses as they operate and grow internationally. As businesses navigate new markets, shifting trade patterns and increasingly complex financial requirements, PhotonPay remains focused on expanding its global network, strengthening strategic partnerships and making financial operations simpler and more accessible.

About PhotonPay

Founded in Hong Kong in 2015, PhotonPay is a global fintech company building a next-generation Financial Operating System (Financial OS). Its API-first architecture brings together multi-asset wallets, global money movement, foreign exchange, global card issuing, embedded finance, and local clearing infrastructure, connecting digital and traditional financial rails within an integrated financial system.

PhotonPay operates 16 offices worldwide, employs nearly 600 people, and holds 35 payment and financial licenses and regulatory authorizations across the Americas, Europe and Asia. The company serves businesses across more than 200 countries and territories.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/photonpay-strengthens-its-global-presence-at-singapore-fintech-festival-2026-302946706.html

SOURCE PhotonPay

Continue Reading

Trending